Application of MTHFR C677T Combined with CYP2C19 Gene Detection after Percutaneous Paclitaxel Eluting Coronary Balloon Dilatation Coronary Angioplasty

Shuo WANG; Qi RU; Xiaochan ZHANG; Zhiyu YANG; Le WANG; Liu LI

doi:10.12259/j.issn.2095-610X.S20220618

Volume 43 Issue 6

Jun. 2022

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2022 > 43(6): 92-98

Shuo WANG, Qi RU, Xiaochan ZHANG, Zhiyu YANG, Le WANG, Liu LI. Application of MTHFR C677T Combined with CYP2C19 Gene Detection after Percutaneous Paclitaxel Eluting Coronary Balloon Dilatation Coronary Angioplasty[J]. Journal of Kunming Medical University, 2022, 43(6): 92-98. doi: 10.12259/j.issn.2095-610X.S20220618

Citation:

Shuo WANG, Qi RU, Xiaochan ZHANG, Zhiyu YANG, Le WANG, Liu LI. Application of MTHFR C677T Combined with CYP2C19 Gene Detection after Percutaneous Paclitaxel Eluting Coronary Balloon Dilatation Coronary Angioplasty[J]. Journal of Kunming Medical University, 2022, 43(6): 92-98. doi: 10.12259/j.issn.2095-610X.S20220618

Citation:

Shuo WANG, Qi RU, Xiaochan ZHANG, Zhiyu YANG, Le WANG, Liu LI. Application of MTHFR C677T Combined with CYP2C19 Gene Detection after Percutaneous Paclitaxel Eluting Coronary Balloon Dilatation Coronary Angioplasty[J]. Journal of Kunming Medical University, 2022, 43(6): 92-98. doi: 10.12259/j.issn.2095-610X.S20220618

PDF( 684 KB)

Application of MTHFR C677T Combined with CYP2C19 Gene Detection after Percutaneous Paclitaxel Eluting Coronary Balloon Dilatation Coronary Angioplasty

doi: 10.12259/j.issn.2095-610X.S20220618

1.
Dept. of Cardiology，Shijiazhuang People’s Hospital，Shijiazhuang Hebei 050031
2.
Dept. of Cardiology，Hebei Medical University First Hospital，Shijiazhuang Hebei 050011，China

Received Date: 2022-03-15
Available Online: 2022-06-07
Publish Date: 2022-06-30

Abstract

Abstract

Objective To investigate the value of MTHFR C677T combined with CYP2C19 gene detection in patients after paclitaxel releasing coronary balloon catheter. Methods 300 patients who underwent paclitaxel releasing coronary balloon catheterization were randomly divided into two groups: first group was the control group, which was treated according to the routine medication scheme; second group was the experimental group. The patients were tested for MTHFR C677T and CYP2C19 genes, and targeted drug intervention was carried out according to the gene test results. Mace events （including cardiac death, myocardial infarction, heart failure, readmission for cardiac reasons, target vessel revascularization）, important organ complications （including cerebral infarction, intracerebral hemorrhage, gastrointestinal bleeding, urinary bleeding, fundus hemorrhage and epistaxis） and adverse drug reactions occurred within 360 days of follow-up （including liver and kidney function injury, gastrointestinal symptoms, rash, decreased platelet or hemoglobin） were recorded. Results （1） The incidence of mace events and important organ complications 360 days after operation in the test group was significantly lower than those in the control group （P < 0.05）. （2） There was no significant difference in the incidence of adverse drug reactions between the experimental group and the control group （P > 0.05）. Conclusions （1） MTHFR C677T and CYP2C19 gene detection in patients after paclitaxel releasing coronary balloon catheter can significantly improve the clinical efficacy. （2） After the detection of MTHFR C677T and CYP2C19 genes in patients after paclitaxel releasing coronary balloon catheter, the medication did not increase the adverse drug reactions.
- MTHFR C677T,
- CYP2C19,
- Percutaneous paclitaxel eluting coronary balloon dilatation coronary angioplasty,
- MACE

FullText(HTML)

References(31)

References

[1]	药物代谢酶和药物作用靶点基因检测技术指南（试行）概要[J/CD]. 实用器官移植电子杂志, 2015, 3（5）: 257-267.
[2]	张晶,丛洪良,曹路,等. 亚甲基四氢叶酸还原酶 A1298C 多态性与高同型半胱氨酸血症的相关性[J]. 中华老年心脑血管病杂志,2017,19(11):1166-1169. doi: 10.3969/j.issn.1009-0126.2017.11.012
[3]	胡小平,刘春莲,武玲,等. MTHFR基因C677T多态性与冠心病患者血浆同型半胱氨酸和叶酸水平相关[J]. 基础医学与临床,2011,31(7):773-776.
[4]	李柳,张晓婵,赵红亮,等. 四氢叶酸还原酶基因多态性与冠心病严重程度的相关性[J]. 昆明医科大学学报,2021,42(5):138-142. doi: 10.12259/j.issn.2095-610X.S20210525
[5]	张琳,王燕,马旭,等. 不稳定心绞痛患者亚甲基四氢叶酸还原酶基因多态性与血清同型半胱氨酸的相关性[J]. 山东大学学报 (医学版),2021,59(6):1671-7554.
[6]	黄晓晖,刘雪姣. 氯吡格雷个体化用药研究进展[J]. 医学研究生学报,2019,32(4):443-448.
[7]	Narasimhalu K,Ang Y K,Tan D S Y,et al. Cost effectiveness of genotype-guided antiplatelet therapy in asian ischemic stroke patients:Ticagrelor as an alternative to clopidogrel in patients with CYP2C19 loss of fun ction mutations[J]. Clin Drug Investig,2020,40(11):1063-1070.
[8]	Wu H,Xiang X,Li D,et al. Efficacy and safety of ticagrelor compared to clopidogrel in patients undergoing percutaneous coronary intervention:a meta-analysis[J]. Curr Pharm Des,2020,26(46):5988-5997. doi: 10.2174/1381612826666200614184007
[9]	付强,苗志林,李占全. 药物洗脱球囊的研究进展[J]. 中国介入心脏病学杂志,2011,19(2):111-113.
[10]	Lyu S Q,Yang Y M,Zhu J,et al. The efficacy and safety of CYP2C19 genotype-guided antiplatelet therapy compared with conventional antiplatelet therapy in patients with acute coronary syndrome or undergoing percutaneous coronary intervention:a meta -analysis of randomized controlled trials[J]. Platelets,2020,31(8):971-980. doi: 10.1080/09537104.2020.1780205
[11]	Moriyama B,Obeng A O,Barbarino J,et al. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP2C19 and voriconazole therapy[J]. Clin Pharmacol Ther,2017,102(1):45-51.
[12]	葛均波, 徐永健. 内科学[M]. 8版. 北京: 人民卫生出版社, 2014: 227.
[13]	《药物涂层球囊临床应用中国专家共识》专家组. 药物涂层球囊临床应用中国专家共识[J]. 中国介入心脏病学杂志,2016,24(2):61-67.
[14]	周忠江,侯玉清. 药物涂层球囊在冠状动脉介入治疗中的应用进展[J]. 中国介入心脏病学杂志,2014,22(3):191-194. doi: 10.3969/j.issn.1004-8812.2014.03.014
[15]	张闻多,于雪,季福绥,等. 《药物涂层球囊治疗冠心病最新专家共识》解读[J]. 中国临床医生杂志,2020,48(8):901-902. doi: 10.3969/j.issn.2095-8552.2020.08.008
[16]	李建平,霍勇,刘平,等. 马来酸依那普利叶酸片降压、降同型半胱氨酸的疗效和安全性[J]. 北京大学学报(医学版),2007,39(6):614-618.
[17]	李建平,卢新政,霍勇,等. H型高血压诊断与治疗专家共识[J]. 中华高血压杂志.,2016,2(24):123-127.
[18]	孙宁玲,秦献辉,李建平,等. 依那普利叶酸片固定复方与依那普利和叶酸自由联合在 H型高血压人群中降低同型半胱氨酸的疗效比较[J]. 中国新药杂志,2009,18(7):1635-1640.
[19]	Ford N F. The metabolism of clopidogrel:CYP2C19 is a minor pathway[J]. Ournal Clin Pharmacol,2016,56(12):1474-1483.
[20]	许晶晶,姜琳,宋莹,等. 以血栓弹力图定义的阿司匹林及氯吡格雷双药抵抗对经皮冠状动脉介入治疗远期预后的评估价值[J]. 中国循环杂志,2019,34(12):1164-1169. doi: 10.3969/j.issn.1000-3614.2019.12.004
[21]	白晓丹,赵超,刘琳娜. MTHFR和MTRR基因多态性与陕西地区汉族人群冠心病发生的相关性研究[J]. 中国药房,2018,29(22):3125-3129. doi: 10.6039/j.issn.1001-0408.2018.22.22
[22]	Hickey S E,Curry C J,Toriello H V. ACMG Practice Guideline:lack of evidence for MTHFR polymorphism testing[J]. Genet Med,2013,15(2):153-156. doi: 10.1038/gim.2012.165
[23]	Balint B,Jepchumba V K,Guéant J L,et al. Mechanisms of homocysteine-induced damage to the endothelial,medial and adventitial layers of the arterial wall[J]. Biochimie,2020,173(6):100-106.
[24]	胡大一,徐希平. 有效控制H型高血压预防卒中的新思路[J]. 中华内科杂志,2008,47(12):967-977.
[25]	Cremers B,Toner J L,Schwartz L B,et al. Inhibition of neointimal hyperplasia with a novel zotarolimus coated balloon catheter[J]. Clin Res Cardiol,2012,101(6):469-476.
[26]	Loh J P,Barbash I M,Waksman R. The current status of drug- coated balloons in percutaneous coronary and peripheral interventions[J]. EuroIntervention,2013,9(8):979-988. doi: 10.4244/EIJV9I8A164
[27]	Barba I,de León G,Martín E,et al. Nuclear magnetic resonance-based metabolomics predicts exercise induced ischemia in patients with suspected coronary artery disease[J]. Magn Reson Med,2008,60(1):27-32. doi: 10.1002/mrm.21632
[28]	郑露, 邵建国 . CYP2C19 的基因多态性与临床〔J〕. 第二军医大学学报, 2007; 28（ 11） : 1262-1265.
[29]	周健, 吕虹, 康熙雄. 中国汉族人群不同性别、年龄、体重指数之间细胞色素氧化CYP2C19基因多态性的检测[J]. 中国临床药理学与治疗学, 2007, 12: 208-213.
[30]	Marcucci R,Giusti B,Paniccia R,et al. Highon-treatment platelet re- activity by ADP and increased risk of MACE in good clopidogrel me- tabolizers[J]. Platelets,2012,23(8):586-593.
[31]	中华医学会心血管病学分会中华心血管病杂志编辑委员会. 抗血小板药物治疗反应多样性临床检测和处理的中国专家建议[J]. 中华心血管病杂志,2014,42(12):986-991. doi: 10.3760/cma.j.issn.0253-3758.2014.12.002

Relative Articles(20)

Relative Articles

[1]	Boyi LI, Ling NIU, Rong MA, Xian ZHANG, Fang LIU, Yan TANG, Cuijuan MIAO, Cheng ZHANG, Zhujun HAN. The Relationship Between T950C Polymorphism in the Promoter Region of Osteoprotegerin Gene and Type 2 Diabetes with Osteoporosis. Journal of Kunming Medical University, 2022, 43(3): 67-73. doi: 10.12259/j.issn.2095-610X.S20220306
[2]	Liya ZHANG, Juan BAO, Jiaping WANG, Yi CAO, Ri JING, Lei ZHANG, Wenqing ZHANG, Tianyi LI. Relationship between the MTHFR C677T Gene Polymorphism and the Collateral Circulation in Patients with Carotid Stenosis. Journal of Kunming Medical University, 2022, 43(2): 96-101. doi: 10.12259/j.issn.2095-610X.S20220219
[3]	Shuo WANG, Yunyan QI, Pu WANG, Yaru WANG, Xiaochan ZHANG, Liu LI. Studies on the Prognosis between Serum sST2 Level and Coronary Heart Disease. Journal of Kunming Medical University, 2022, 43(1): 112-117. doi: 10.12259/j.issn.2095-610X.S20220115
[4]	Bo-yi LI, Ling NIU, Rong MA, Xian ZHANG, Fang LIU, Yan TANG, Cui-juan MIAO, Zhu-jun HAN, Cheng ZHANG. The Relationship between T950C Polymorphism in the Promoter Region of Osteoprotegerin Gene and Type 2 Diabetes with Osteoporosis in Kunming Area. Journal of Kunming Medical University, 2021, 43(): 1-8. doi: 10.12259/j.issn.2095-610X.S20211112
[5]	Hong-yu PENG, Zhi-xiang FAN, Yan-jie ZHANG, Xin SHU, Fu-lin ZHANG, Li LONG. Correlation between CYP11B2 Gene -344 C/T Polymorphism and Essential Hypertension in Yi Minority of Yunnan Shuanghe Township. Journal of Kunming Medical University, 2021, 42(7): 7-12. doi: 10.12259/j.issn.2095-610X.S20210702
[6]	Ting PI, Yue-qin LIANG, Li DING, Ling YANG, Ying-ying XIANG. Distribution Characteristics of MTHFR 677C > T Gene Polymorphism in Pregnant Women and Its Correlation with Hypertension during Pregnancy. Journal of Kunming Medical University, 2021, 42(2): 86-90. doi: 10.12259/j.issn.2095-610X.S20210215
[7]	Liu LI, Xiao-chan ZHANG, Qi RU, Shuo WANG, Quo-qing QI, Hong-liang ZHAO. The Association of Methylenetetrahydrofolate Reductase Gene Polymorphism with Coronary Heart Disease. Journal of Kunming Medical University, 2021, 42(5): 138-142. doi: 10.12259/j.issn.2095-610X.S20210525
[8]	Shuo WANG, Ai SUN, Hui-jie ZHANG, Yang YOU, Li-ye WEI, Liu LI. Application of Myocardial Ischemia Preconditioning in Paclitaxel-Eluting Coronary Balloon Dilatation Coronary Angioplasty Catheterization. Journal of Kunming Medical University, 2021, 42(12): 89-94. doi: 10.12259/j.issn.2095-610X.S20211225
[9]	Li Qi . Mutation Analysis of CIB2 196C>T 272T>C and 297 C>G in Patients with Non-syndromic Hearing Impairment. Journal of Kunming Medical University, 2018, 39(05): 7-10.
[10]	Song Fei , Xiang Ying Ying , Mao Zhi Jian , Zhang Xiao Wen . Comparative Study on Releasing Characteristics of Paclitaxel Chitosan Membranes by Two Different Preparative Methods. Journal of Kunming Medical University, 2017, 38(01): 1-7.
[11]	Li Lin , Li Ji Yi , Wang De Zhao , Liu Wei . 武汉地区123例冠心病患者CYP2C19基因多态性分布. Journal of Kunming Medical University, 2017, 38(06): 60-63.
[12]	Wang Xiang Yun . . Journal of Kunming Medical University,
[13]	Dai Shu Ying . . Journal of Kunming Medical University,
[14]	Jian Bin . . Journal of Kunming Medical University,
[15]	Li Xue Tao . . Journal of Kunming Medical University, 2013, 34(04): 1-1.
[16]	Han Jiang Qiong . . Journal of Kunming Medical University,
[17]	He Ying Hong . . Journal of Kunming Medical University,
[18]	Chen Xi . . Journal of Kunming Medical University,
[19]	Nian Xin . The Preliminary Analysis of the FOXC2 C-1702T Polymorphism is Associated with Cholesterol. Journal of Kunming Medical University, 2012, 33(02): 1-1.
[20]	. The Application of Intraaortic Balloon Counterpulsation in Acute Coronary Syndrome. Journal of Kunming Medical University,